The goal to improve management of chronic HCV patients calls for a joint effort between researchers, diagnostic laboratories and clinicians. An accurate diagnostic profile is essential for predicting patients’ response and individualising combination therapy. This demands a tool that can precisely distinguish true signals from background noise.
The latest quantitative HCV RNA assay from Roche Molecular Diagnostics is based on a novel Dual Probe approach with an optimised automated extraction and amplification procedure. This ensures highly sensitive detection of HCV RNA across different HCV genotypes with accurate and reproducible results at low viral loads. Thus resulting in optimised treatment and overall patient benefits as we work towards putting a stop to the spread of HCV.